clinical trials

News

Ultragenyx to slash costs after Angelman trial failure

Ultragenyx's therapy for the rare genetic disorder Angelman syndrome, apazunersen, has flunked a late-stage trial, crashing its share price.

News

Akeso's ivonescimab extends survival in PD-L1+ lung cancer

Akeso's PD-1xVEGF drug ivonescimab improves survival in another late-stage Chinese trial, ahead of a key international study readout later this year.

News

PMV cues up filing for first p53-directed cancer therapy

PMV is preparing to file for approval of its first-in-class oral p53 protein reactivator, rezatopopt, for ovarian cancer in the first quarter of 2027.

News

GSK pushes 'next-generation' mRNA flu shot into phase 3

Buoyed by positive data in a phase 2 trial, GSK will start a phase 3 programme for an mRNA-based flu shot targeting both HA and NA flu antigens.

News

Novartis sets sights on new oral MS drug after phase 3 wins

Novartis' oral BTK inhibitor remibrutinib has shown efficacy in a pair of phase 3 trials in multiple sclerosis, boosting its blockbuster credentials.

News

Novartis halts CAR-T trials after patient deaths

Novartis stops eight trials of CAR-T rap-cel in autoimmune diseases after three deaths, with BMS also halting studies of zola-cel as a precaution.

Ultragenyx to slash costs after Angelman trial failure

Akeso's ivonescimab extends survival in PD-L1+ lung cancer

PMV cues up filing for first p53-directed cancer therapy

GSK pushes 'next-generation' mRNA flu shot into phase 3

Novartis sets sights on new oral MS drug after phase 3 wins

Novartis halts CAR-T trials after patient deaths

Getting predictive technologies to patients, with Concr

Discover a new era of healthcare panel engagement: Grounded ...

clinical trials

Editor's Picks